3,907 results match your criteria Carcinoma in Situ of the Urinary Bladder

Urinary Large Cell Neuroendocrine Carcinoma: A Clinicopathologic Analysis of 22 Cases.

Am J Surg Pathol 2021 Jun 2. Epub 2021 Jun 2.

Departments of Pathology Radiology Medical Oncology, British Columbia Cancer Vancouver Centre Department of Urology, Vancouver General Hospital Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada Department of Pathology, MD Anderson Cancer Center, Houston, TX.

Large cell neuroendocrine carcinoma (LCNEC) of the urinary tract is a rare disease. We present a relatively large retrospective cohort of urinary LCNEC, 20 from the urinary bladder, and 2 from the ureter, from a single institution. The patients included 16 men and 6 women with a median age of 74. Read More

View Article and Full-Text PDF

The diagnostic challenge of suspicious or positive malignant urine cytology findings when cystoscopy findings are normal: an outpatient blue-light flexible cystoscopy may solve the problem.

Scand J Urol 2021 May 26:1-5. Epub 2021 May 26.

Department of Urology, Helsingborg Hospital, Helsingborg, Sweden.

Purpose: To investigate whether outpatient blue-light flexible cystoscopy could solve the diagnostic challenge of positive or suspicious urine cytology findings despite normal white-light flexible cystoscopy results and normal findings on computerized tomography urography, in patients investigated for urothelial cancer.

Material And Methods: In a multicentre study, a total of 70 examinations were performed with the use of blue-light flexible cystoscopy (photodynamic diagnosis) after intravesical instillation of the fluorescence agent hexaminolevulinate. The examination started with a conventional white-light flexible cystoscopy and then the settings were switched to use blue light. Read More

View Article and Full-Text PDF

Dynamically crosslinked polydimethylsiloxane-based polyurethanes with contact-killing antimicrobial properties as implantable alloplasts for urological reconstruction.

Acta Biomater 2021 May 9. Epub 2021 May 9.

Materials Research Centre, Indian Institute of Science, Bangalore-560012, India; Center for Biosystems Science and Engineering, Indian Institute of Science, Bangalore-560012, India. Electronic address:

A large population of patients is reported to suffer from urinary bladder-associated irreversible physiological disorders, rationalizing a continuous surge for structural and functional substitutes of urinary tissues, including ureters, bladder-wall, and urethra. The current gold standard for bladder reconstruction, an autologous gastrointestinal graft, is proven not to be an ideal substitute in the clinic. While addressing this unmet clinical need, a unique platform of antimicrobial polydimethyl siloxane-modified polyurethanes (TPU/PDMS) is designed and developed for its potential application as a urological implant. Read More

View Article and Full-Text PDF

UroVysion fluorescence in situ hybridization in urothelial carcinoma: a narrative review and future perspectives.

Transl Androl Urol 2021 Apr;10(4):1908-1917

Department of Nephro-urology, Nagoya City University, Graduate School of Medical Sciences, Nagoya, Japan.

The number of patients with urothelial carcinoma (UC) is high, with a corresponding demand for detecting UC easily and non-invasively. Cystoscopy and urine cytology, with widely known diagnostic accuracies, are the gold standards for identifying UC originating from the bladder. However, cystoscopy or other tests, such as ureteroscopy or retrograde pyelography, are uncomfortable for patients. Read More

View Article and Full-Text PDF

The Usefulness of Cell-Based and Liquid-Based Urine Tests in Clarifying the Diagnosis and Monitoring the Course of Urothelial Carcinoma. Identification of Novel, Potentially Actionable, and Somatic Mutations.

J Pers Med 2021 Apr 30;11(5). Epub 2021 Apr 30.

Laboratory of Medical Genetics of the "Genos" Partnership-R&D Division, 91-033 Lodz, Poland.

Bladder cancer is one of the most common cancers in global statistics. One of the issues associated with this disease is the high incidence of cases with delayed diagnosis and what factors correlate with worse treatment outcomes. A possible reason for this may be the rather limited availability of non-invasive diagnostic tools. Read More

View Article and Full-Text PDF

Noninvasive papillary urothelial carcinoma with pathological features in between low and high grades: A case report.

Medicine (Baltimore) 2021 Apr;100(17):e25693

Department of Pathology, The First Affiliated Hospital and College of Basic Medical Sciences, China Medical University, Shenyang, Liaoning, China.

Rationale: Urinary bladder urothelial carcinoma is the most common malignant tumor in the urinary system, and noninvasive papillary urothelial carcinoma (NIPUC) comprises most bladder malignancies. NIPUC grading is important for therapeutic and clinical protocol selection. Here, we report a case of NIPUC with pathological features in between low (LG-NIPUC) and high (HG-NIPUC) grades NIPUC. Read More

View Article and Full-Text PDF

Urine cytology findings in patients with biopsy-confirmed urothelial carcinoma in situ with plasmacytoid features.

Cancer Cytopathol 2021 Apr 26. Epub 2021 Apr 26.

Department of Laboratory Medicine, Cleveland Clinic, Cleveland, Ohio.

Background: Urine cytology is an important screening tool in the diagnosis of high-grade urothelial carcinoma. Diagnosis in urine samples follows criteria outlined by The Paris System for Reporting Urinary Cytology (TPS). However, cytologic characteristics of the recently described urothelial carcinoma in situ with plasmacytoid features (P-CIS) have not been described, and it is unknown whether they conform to TPS criteria for high-grade urothelial carcinoma. Read More

View Article and Full-Text PDF

Imaging of Bladder Cancer: Standard Applications and Future Trends.

Medicina (Kaunas) 2021 Mar 1;57(3). Epub 2021 Mar 1.

Radiology Department, Urology and Nephrology Center, Mansoura University, Mansoura 35516, Egypt.

The evolution in imaging has had an increasing role in the diagnosis, staging and follow up of bladder cancer. Conventional cystoscopy is crucial in the diagnosis of bladder cancer. However, a cystoscopic procedure cannot always depict carcinoma in situ (CIS) or differentiate benign from malignant tumors prior to biopsy. Read More

View Article and Full-Text PDF

Estimated Costs and Long-term Outcomes of Patients With High-Risk Non-Muscle-Invasive Bladder Cancer Treated With Bacillus Calmette-Guérin in the Veterans Affairs Health System.

JAMA Netw Open 2021 03 1;4(3):e213800. Epub 2021 Mar 1.

Durham Veterans Affairs Health Care System, Durham, North Carolina.

Importance: Management of high-risk non-muscle-invasive bladder cancer (NMIBC) represents a clinical challenge due to high failure rates despite prior bacillus Calmette-Guérin (BCG) therapy.

Objective: To describe real-world patient characteristics, long-term outcomes, and the economic burden in a population with high-risk NMIBC treated with BCG therapy.

Design, Setting, And Participants: This retrospective cohort study identified 412 patients with high-risk NMIBC from 63 139 patients diagnosed with bladder cancer who received at least 1 dose of BCG within Department of Veterans Affairs (VA) centers across the US from January 1, 2000, to December 31, 2015. Read More

View Article and Full-Text PDF

Photodynamic diagnostic ureteroscopy using the VISERA ELITE video system for diagnosis of upper-urinary tract urothelial carcinoma: a prospective cohort pilot study.

BMC Urol 2021 Mar 25;21(1):45. Epub 2021 Mar 25.

Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1, Shikata-cho, Kita-ku, Okayama, 700-8558, Japan.

Background: The advantages of photodynamic diagnostic technology using 5-aminolevulinic acid (ALA-PDD) have been established. The aim of this prospective cohort study was to evaluate the usefulness of ALA-PDD to diagnose upper tract urothelial carcinoma (UT-UC) using the Olympus VISERA ELITE video system.

Methods: We carried out a prospective, interventional, non-randomized, non-contrast and open label cohort pilot study that involved patients who underwent ureterorenoscopy (URS) to detect UT-UC. Read More

View Article and Full-Text PDF

Oncological impact of inflammatory biomarkers in elderly patients treated with radical cystectomy for urothelial bladder cancer.

Arab J Urol 2020 Aug 26;19(1):2-8. Epub 2020 Aug 26.

Unit of Oncologic Minimally-Invasive Urology and Andrology, Careggi Hospital, Florence, Italy.

Objective: To evaluate the impact of preoperative markers of systemic inflammation on complications and oncological outcomes in patients aged ≥75 years treated with radical cystectomy (RC) for urothelial bladder cancer (UBC).

Patients And Methods: The clinical data of 694 patients treated with open RC for UBC at our institution between January 2008 and December 2015 were retrospectively reviewed. Patients aged <75 years, with distant metastases, other-than-urothelial histological type, comorbidities that could affect the systemic inflammatory markers, and patients who received neoadjuvant chemotherapy were excluded. Read More

View Article and Full-Text PDF

Presumptive malignant transformation of chronic polypoid cystitis into an apical transitional cell carcinoma without BRAF mutation in a young female dog.

J Vet Intern Med 2021 May 19;35(3):1551-1557. Epub 2021 Mar 19.

Tufts University Cummings School of Veterinary Medicine, Internal Medicine, North Grafton, Massachusetts, USA.

A 3-year-old spayed female English Springer Spaniel was presented twice 4 months apart for investigation of hematuria and pollakiuria without urinary tract infection. Both ultrasound examinations identified a stable craniodorsal bladder wall thickening. The first cystoscopic biopsy samples indicated lymphoplasmacytic cystitis and the second polypoid cystitis. Read More

View Article and Full-Text PDF

The Prognostic Impact of Tumor Architecture for Upper Urinary Tract Urothelial Carcinoma: A Propensity Score-Weighted Analysis.

Front Oncol 2021 25;11:613696. Epub 2021 Feb 25.

Department of Urology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan.

Purpose: To assess the association of tumor architecture with cancer recurrence, metastasis, and cancer-specific survival (CSS) in patients treated with radical nephroureterectomy (RNU) for upper urinary tract urothelial carcinoma (UTUC) in Taiwan.

Materials And Methods: Data were collected from 857 patients treated with RNU between January 2005 and August 2016 in our hospital. Pathologic slides were reviewed by genitourinary pathologists. Read More

View Article and Full-Text PDF
February 2021

Fluorescence In Situ Hybridization in Urine Samples (UroVysion Kit).

Sara Bravaccini

Methods Mol Biol 2021 ;2292:35-48

Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.

Cystoscopy is considered the standard approach to the diagnostic workup of urinary symptoms. It has high sensitivity and specificity for papillary tumors of the bladder but low sensitivity and specificity for flat lesions. It is also expensive and may cause discomfort and complications. Read More

View Article and Full-Text PDF

Intratumoral heterogeneity of surrogate molecular subtypes in urothelial carcinoma in situ of the urinary bladder: implications for prognostic stratification of high-risk non-muscle-invasive bladder cancer.

Virchows Arch 2021 Mar 1. Epub 2021 Mar 1.

Department of Urology, Helios University Hospital Wuppertal, Wuppertal, Germany.

Reliable factors predicting the disease course of non-muscle-invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) are unavailable. Molecular subtypes have potential for prognostic stratification of muscle-invasive bladder cancer, while their value for CIS patients is unknown. Here, the prognostic impact of both clinico-pathological parameters, including CIS focality, and immunohistochemistry-based surrogate subtypes was analyzed in a cohort of high-risk NMIBC patients with CIS. Read More

View Article and Full-Text PDF

Complete Transurethral Resection before Radical Cystectomy May Improve Oncological Outcomes.

Urol Int 2021 Feb 24:1-8. Epub 2021 Feb 24.

Department of Urology, University Hospital of Rennes, Rennes, France.

Objectives: The objective of this study was to assess the impact of complete transurethral resection of bladder tumors (TURBTs) before radical cystectomy on pathological and oncological outcomes of patients with muscle-invasive bladder cancer (MIBC) and high-risk non-MIBC.

Materials And Methods: The charts of all patients who underwent radical cystectomy for bladder cancer in 2 academic departments of urology between 1996 and 2016 were retrospectively reviewed. Patients were divided into 2 groups according to the completeness of the last endoscopic resection before radical cystectomy: macroscopically complete transurethral resection (complete) or macroscopically incomplete transurethral resection (incomplete). Read More

View Article and Full-Text PDF
February 2021

The impact of carcinoma in situ in ureteral margins during radical cystectomy: A case-controlled study.

Urol Oncol 2021 Feb 9. Epub 2021 Feb 9.

Department of urology, Hospital Foch, Versailles - Saint-Quentin-en-Yvelines university, Suresnes France.

Background And Objective: The presence of carcinoma in situ (Cis) in association with bladder cancer is associated with a poor prognosis. However, the prognosis associated with the presence of Cis in ureteral margins (CUM) during radical cystectomy has been poorly defined. To assess the prognosis associated with the presence of Cis in ureteral margins in patients with pM0 bladder cancer who have not undergone neoadjuvant chemotherapy. Read More

View Article and Full-Text PDF
February 2021

Contemporary Outcomes of Patients with Nonmuscle-Invasive Bladder Cancer Treated with bacillus Calmette-Guérin: Implications for Clinical Trial Design.

J Urol 2021 Jun 27;205(6):1612-1621. Epub 2021 Jan 27.

Department of Urology, University of Texas MD Anderson Cancer Center, Houston, Texas.

Purpose: Recurrent disease after bacillus Calmette-Guérin treatment presents a therapeutic challenge. To aid trial development, the U.S. Read More

View Article and Full-Text PDF

Evidence of BK Polyomavirus Infection in Urothelial but not Renal Tumors from a Single Center Cohort of Kidney Transplant Recipients.

Viruses 2021 Jan 3;13(1). Epub 2021 Jan 3.

Virology Unit, Department of Translational Medicine, Novara Medical School, 28100 Novara, Italy.

Emerging evidence indicates that reactivation of BK polyomavirus (BKPyV) in the kidney and urothelial tract of kidney transplant recipients (KTRs) may be associated with cancer in these sites. In this retrospective study of a single center cohort of KTRs ( = 1307), 10 clear cell renal cell carcinomas and 5 urinary bladder carcinomas were analyzed from 15 KTRs for the presence of BKPyV infection through immunohistochemistry and fluorescent in situ hybridization (FISH). Three of these patients had already exhibited biopsy-proven polyomavirus-associated nephropathies (PyVAN). Read More

View Article and Full-Text PDF
January 2021

The clinicopathological characteristics of muscle-invasive bladder recurrence in upper tract urothelial carcinoma.

Cancer Sci 2021 Mar 11;112(3):1084-1094. Epub 2021 Jan 11.

Department of Urology, Keio University School of Medicine, Tokyo, Japan.

This study aimed to clarify the clinical characteristics and oncological outcomes of patients with upper tract urothelial carcinoma (UTUC) who developed muscle-invasive bladder cancer (MIBC) after radical nephroureterectomy (RNU). We identified 966 pTa-4N0-2M0 patients with UTUC who underwent RNU and clarified the risk factors for MIBC progression after initial intravesical recurrence (IVR). We also identified 318 patients with primary pT2-4N0-2M0 MIBC to compare the oncological outcomes with those of patients with UTUC who developed or progressed to MIBC. Read More

View Article and Full-Text PDF

Cost-Effectiveness Analysis of Pembrolizumab for Bacillus Calmette-Guérin-Unresponsive Carcinoma In Situ of the Bladder.

J Urol 2021 May 21;205(5):1326-1335. Epub 2020 Dec 21.

Department of Urology, Mayo Clinic, Rochester, Minnesota.

Purpose: Patients with bacillus Calmette-Guérin-unresponsive carcinoma in situ are treated with radical cystectomy or salvage intravesical chemotherapy. Recently, pembrolizumab was approved for bacillus Calmette-Guérin-unresponsive carcinoma in situ.

Materials And Methods: We used a decision-analytic Markov model to compare pembrolizumab, salvage intravesical chemotherapy (with gemcitabine-docetaxel induction+monthly maintenance) and radical cystectomy for patients with bacillus Calmette-Guérin-unresponsive carcinoma in situ who are radical cystectomy candidates (index patient 1) or are unwilling/unable to undergo radical cystectomy (index patient 2). Read More

View Article and Full-Text PDF

Reactivation of BK Polyomavirus in Urine Cytology is Not Associated with Urothelial Cell Carcinoma.

Viruses 2020 12 8;12(12). Epub 2020 Dec 8.

Department of Pathology, GROW-School for Oncology & Developmental Biology, Maastricht University, Medical Centre+, 6229 HX Maastricht, The Netherlands.

BK polyomavirus (BKPyV) has been associated with some high-grade and special urothelial cell carcinoma (UCC) subtypes in immunosuppressed patients. Here, we evaluated the relationship of BKPyV-positive urine cytology specimens (UCS) with UCC. A large single-institution database was retrospectively searched for UCS positive for decoy cells, suggesting BKPyV infection. Read More

View Article and Full-Text PDF
December 2020

Chloride Intracellular Channel Protein 1 (CLIC1) Ιs Over-expressed in Muscle Invasive Urinary Bladder Cancer.

Anticancer Res 2020 Dec;40(12):6879-6884

Department of Microscopic Morphology/Histology, Angiogenesis Research Center Timisoara, Victor Babes University of Medicine and Pharmacy, Timisoara, Romania

Background/aim: Invasive bladder cancer mortality remains high despite progresses made in early diagnosis and surgical procedures. Thus, there is a need to define new markers for bladder cancer. CLIC1 has not been previously studied in bladder cancer and thus, we aimed to assess its immunohistochemical expression in relation to different stages of bladder cancer development. Read More

View Article and Full-Text PDF
December 2020

Intravesical Bacillus Calmette-Guerin and its complications: 12 years of learning experience in a single local institution.

Singapore Med J 2020 Dec 2. Epub 2020 Dec 2.

Department of Urology, Singapore General Hospital, Singapore.

Introduction: Intravesical Bacillus Calmette-Guerin (BCG) therapy is the standard adjuvant treatment for non-muscle invasive bladder carcinoma (NMIBC) with carcinoma in situ, in addition to tumour resection. We aimed to study BCG complications that preclude adequate treatment of NMIBC in an Asian population.

Methods: This retrospective study was conducted using a large, prospectively maintained bladder cancer database. Read More

View Article and Full-Text PDF
December 2020

Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial.

Lancet Oncol 2021 01 27;22(1):107-117. Epub 2020 Nov 27.

Department of Urology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.

Background: BCG is the most effective therapy for high-risk non-muscle-invasive bladder cancer. Nadofaragene firadenovec (also known as rAd-IFNa/Syn3) is a replication-deficient recombinant adenovirus that delivers human interferon alfa-2b cDNA into the bladder epithelium, and a novel intravesical therapy for BCG-unresponsive non-muscle-invasive bladder cancer. We aimed to evaluate its efficacy in patients with BCG-unresponsive non-muscle-invasive bladder cancer. Read More

View Article and Full-Text PDF
January 2021

Comparison Of Recurrence Rate Between "EN BLOC" Resection Of Bladder Tumour And Conventional Technique For Non-Muscle Invasive Bladder Cancer.

J Ayub Med Coll Abbottabad 2020 Oct-Dec;32(4):435-440

Urology Section, Aga Khan University Hospital Karachi, Pakistan.

Background: Conventional transurethral resection of urinary bladder tumour (TURBT) using a wire loop diathermy violates the basic principle of oncological surgery, i.e. dissection through normal tissue. Read More

View Article and Full-Text PDF
January 2021

The discovery of bacterial biofilm in patients with muscle invasive bladder cancer.

APMIS 2021 May 26;129(5):265-270. Epub 2021 Feb 26.

Department of Urology, Zealand University Hospital, Roskilde, Denmark.

The carcinogenic effects of microorganisms have been discovered in multiple cancer types. In urology, the development of squamous cell carcinoma of the bladder due to the parasitic infection with Schistosoma Mansoni is widely accepted. The oncogenic potential of biofilms has been studied in colorectal cancer and experimental studies have shown that bacteria such as Escherichia coli drive the development of colorectal cancer. Read More

View Article and Full-Text PDF

Response to Neoadjuvant Chemotherapy and Survival in Micropapillary Urothelial Carcinoma: Data From a Tertiary Referral Center and the Surveillance, Epidemiology, and End Results (SEER) Program.

Clin Genitourin Cancer 2021 Apr 14;19(2):144-154. Epub 2020 Oct 14.

Department of Urology, University of Washington, Seattle, WA; Fred Hutchinson Cancer Research Center, Seattle, WA. Electronic address:

Background: Micropapillary urothelial carcinoma (MPC) is a rare urothelial carcinoma variant with conflicting data guiding clinical practice. In this study, we explored oncologic outcomes in relation to neoadjuvant chemotherapy (NAC) in a retrospective cohort of patients with MPC, alongside data from Surveillance, Epidemiology, and End Results (SEER)-Medicare.

Patients And Methods: We retrospectively identified patients with MPC or conventional urothelial carcinoma (CUC) without any variant histology undergoing radical cystectomy (RC) in our institution (2003-2018). Read More

View Article and Full-Text PDF

Stage T1 bladder cancer: diagnostic criteria and pitfalls.

Pathology 2021 Jan 3;53(1):67-85. Epub 2020 Nov 3.

Department of Pathology, Indiana University School of Medicine, Indianapolis, USA; Department of Urology, Indiana University School of Medicine, Indianapolis, USA. Electronic address:

Accurate pathological staging is crucial for patient management. Patients with T1 bladder cancer are at risk of recurrence, progression, and death of cancer. Recognition of early invasion (stage T1 disease) in urothelial carcinoma remains one of the most challenging areas in urological surgical pathology practice. Read More

View Article and Full-Text PDF
January 2021

MDM2 gene amplification as selection tool for innovative targeted approaches in PD-L1 positive or negative muscle-invasive urothelial bladder carcinoma.

J Clin Pathol 2020 Nov 3. Epub 2020 Nov 3.

Policlinico Universitario Fondazione Andrea Gemelli, Rome, Italy.

Aims: According to The Cancer Genome Atlas (TCGA), around 9% of bladder carcinomas usually show abnormalities of the murine double minute 2 (MDM2) gene, but a few studies have been investigated them. We profiled MDM2 gene amplification in a series of urothelial carcinomas (UC) considering the molecular subtypes and expression of programmed death ligand 1 (PD-L1).

Methods: 117 patients with muscle-invasive UC (pT2-3) without (N0) or with (N+) lymph-node metastases were revised. Read More

View Article and Full-Text PDF
November 2020